Sugi Predict

Sugi Predict / Compounds / SCHEMBL9609

SCHEMBL9609

SCHEMBL9609

COc1cccc(C=NO)c1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.53
▸ HPGD P15428 5/20 0.53
▸ HTT P42858 2/20 0.53
▸ ALDH1A1 P00352 3/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ CA12 O43570 1/20 0.46
▸ USP2 O75604 1/20 0.45
▸ MAPT P10636 4/20 0.44
▸ NFE2L2 Q16236 2/20 0.43
▸ TLR2 O60603 1/20 0.43
▸ ERN1 O75460 1/20 0.43
▸ TLR1 Q15399 1/20 0.43
▸ TLR6 Q9Y2C9 1/20 0.43
▸ GRIN2D O15399 2/20 0.42
▸ GRIN3B O60391 2/20 0.42
▸ GRIN1 Q05586 2/20 0.42
▸ GRIN2A Q12879 2/20 0.42
▸ GRIN2B Q13224 2/20 0.42
▸ GRIN2C Q14957 2/20 0.42
▸ GRIN3A Q8TCU5 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13002981 1.00 LMNA (0.53) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL9608 1.00 LMNA (0.53) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL29792596 1.00 LMNA (0.53) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL20148159 0.84 HPGD (0.42) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL20150849 0.84 HPGD (0.42) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL2186863 0.81 HPGD (0.56) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL2186861 0.81 HPGD (0.56) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL2160891 0.81 HPGD (0.69) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL30210927 0.81 HPGD (0.69) LMNAHPGDHTTALDH1A1L3MBTL1
SCHEMBL2420718 0.81 HPGD (0.69) LMNAHPGDHTTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 — — US disclosed
EP-4477220-A2 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-12-18 — — EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 — — EP disclosed
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-07 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
EP-4031547-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2022-07-27 — — EP disclosed
CN-114728962-A Plasma kallikrein inhibitors and uses thereof 武田药品工业有限公司 2022-07-08 — — CN disclosed
WO-2021055621-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2021-03-25 — — WO disclosed
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF CHARLES RIVER LABORATORIES, INC. 2021-03-18 — — US disclosed
US-20180118754-A1 COMPOUNDS RESPIVERT LTD. (GB) 2018-05-03 — — US disclosed
US-20120208799-A1 COMPOUNDS RESPIVERT LTD (GB) 2012-08-16 — — US disclosed
WO-2011048111-A1 COMPOUNDS RESPIVERT LIMITED (GB) 2011-04-28 — — WO disclosed
US-20100311790-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHIEMCAL COMPANY LIMITED (JP) 2010-12-09 — — US disclosed
US-20100227884-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-09 — — US disclosed
EP-2215062-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME Sumitomo Chemical Company, Limited (JP) 2010-08-11 — — EP disclosed
EP-2200988-A1 N-BENZYL QUINOLINE-6-CARBOXAMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME Sumitomo Chemical Company, Limited (JP) 2010-06-30 — — EP disclosed
WO-2009157527-A1 BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-30 — — WO disclosed
WO-2009157528-A1 BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-30 — — WO disclosed
WO-2009069792-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 — — WO disclosed
WO-2009051086-A1 N-BENZYL QUINOLINE-6-CARBOXAMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 LMNA 1626/4885HPGD 542/4885HTT 4701/4885
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 LMNA 1626/4885HPGD 542/4885HTT 4701/4885
US-20100227884-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME NAAA, ATL3, ACSL5 LMNA 2414/4885HPGD 3379/4885HTT 1333/4885
US-20100311790-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME ATL3, NAT1, C5 LMNA 2049/4885HPGD 4316/4885HTT 480/4885
US-20120208799-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 LMNA 1817/4885HPGD 75/4885HTT 1839/4885
US-20180118754-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 LMNA 1817/4885HPGD 75/4885HTT 1839/4885
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 LMNA 1626/4885HPGD 542/4885HTT 4701/4885
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 LMNA 1626/4885HPGD 542/4885HTT 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.